Compugen Ltd. (NASDAQ:CGEN) is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.09 per share.
For the full year, analysts predict loss of $ 0.36 per share.
Stock Performance
Shares of Compugen Ltd. traded up $ 0.54 or 4.13 percent on Wednesday, reaching $ 13.61 with volume of 1.02 million shares. Compugen Ltd. has traded high as $ 13.92 and has cracked $ 13.31 on the downward trend
The closing price of $ 13.61, representing a 174.58 % increase from the 52 week low of $ 4.76 and a 34.32 % decrease over the 52 week high of $ 19.90.
The company has a market capital of $ 1.11 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Compugen Ltd. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cgen.com
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The companys therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program.
